A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy

Shuji Terao; Toshiro Shirakawa; Bishnu Acharya; Masahiro Miyata; Nobuyuki Hinata; Kazushi Tanaka; Atsushi Takenaka; Isao Hara; Michio Naoe; Kohzo Fuji; Takatsugu Okegawa; Eiji Higashihara; Sadao Kamidono; Masato Fujisawa; Akinobu Gotoh

A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy

Shuji Terao, Toshiro Shirakawa, Bishnu Acharya, Masahiro Miyata, Nobuyuki Hinata, Kazushi Tanaka, Atsushi Takenaka, Isao Hara, Michio Naoe, Kohzo Fuji, Takatsugu Okegawa, Eiji Higashihara, Sadao Kamidono, Masato Fujisawa, Akinobu Gotoh

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background: The effects on quality of life (QOL) after a Phase I/II clinical trial of a combination of osteocalcin promoter-driven herpes simplex virus thymidine kinase (Ad-OC-TK) gene therapy and valacyclovir (VAL) were investigated for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: The QOL of six patients was prospectively assessed after gene therapy on days 0, 14, and 28. A modified questionnaire was created based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire's prostate cancer-specific module (EORTC QLQ-PR25). Results: The scores of all items significantly improved along with the total score. Further, bodily pain was significantly reduced on day 28. Moreover, the rate of change in the serum prostate-specific antigen levels from day 0 to day 28 was significantly correlated with the rate of change in bodily pain. Conclusion: In this clinical trial, Ad-OC-TK plus VAL treatment significantly improved the short-term QOL and bodily pain of patients with localized recurrence or bone metastases of HRPC.

Original language	English
Pages (from-to)	1533-1537
Number of pages	5
Journal	Anticancer Research
Volume	29
Issue number	5
State	Published - May 2009
Externally published	Yes

Keywords

Adenovirus vector
Clinical trial
Gene therapy
Hormone refractory prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0be89ca4c75843df91b30623fc737d50,

title = "A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy",

abstract = "Background: The effects on quality of life (QOL) after a Phase I/II clinical trial of a combination of osteocalcin promoter-driven herpes simplex virus thymidine kinase (Ad-OC-TK) gene therapy and valacyclovir (VAL) were investigated for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: The QOL of six patients was prospectively assessed after gene therapy on days 0, 14, and 28. A modified questionnaire was created based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire's prostate cancer-specific module (EORTC QLQ-PR25). Results: The scores of all items significantly improved along with the total score. Further, bodily pain was significantly reduced on day 28. Moreover, the rate of change in the serum prostate-specific antigen levels from day 0 to day 28 was significantly correlated with the rate of change in bodily pain. Conclusion: In this clinical trial, Ad-OC-TK plus VAL treatment significantly improved the short-term QOL and bodily pain of patients with localized recurrence or bone metastases of HRPC.",

keywords = "Adenovirus vector, Clinical trial, Gene therapy, Hormone refractory prostate cancer",

author = "Shuji Terao and Toshiro Shirakawa and Bishnu Acharya and Masahiro Miyata and Nobuyuki Hinata and Kazushi Tanaka and Atsushi Takenaka and Isao Hara and Michio Naoe and Kohzo Fuji and Takatsugu Okegawa and Eiji Higashihara and Sadao Kamidono and Masato Fujisawa and Akinobu Gotoh",

year = "2009",

month = may,

language = "英語",

volume = "29",

pages = "1533--1537",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "5",

}

TY - JOUR

T1 - A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy

AU - Terao, Shuji

AU - Shirakawa, Toshiro

AU - Acharya, Bishnu

AU - Miyata, Masahiro

AU - Hinata, Nobuyuki

AU - Tanaka, Kazushi

AU - Takenaka, Atsushi

AU - Hara, Isao

AU - Naoe, Michio

AU - Fuji, Kohzo

AU - Okegawa, Takatsugu

AU - Higashihara, Eiji

AU - Kamidono, Sadao

AU - Fujisawa, Masato

AU - Gotoh, Akinobu

PY - 2009/5

Y1 - 2009/5

N2 - Background: The effects on quality of life (QOL) after a Phase I/II clinical trial of a combination of osteocalcin promoter-driven herpes simplex virus thymidine kinase (Ad-OC-TK) gene therapy and valacyclovir (VAL) were investigated for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: The QOL of six patients was prospectively assessed after gene therapy on days 0, 14, and 28. A modified questionnaire was created based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire's prostate cancer-specific module (EORTC QLQ-PR25). Results: The scores of all items significantly improved along with the total score. Further, bodily pain was significantly reduced on day 28. Moreover, the rate of change in the serum prostate-specific antigen levels from day 0 to day 28 was significantly correlated with the rate of change in bodily pain. Conclusion: In this clinical trial, Ad-OC-TK plus VAL treatment significantly improved the short-term QOL and bodily pain of patients with localized recurrence or bone metastases of HRPC.

AB - Background: The effects on quality of life (QOL) after a Phase I/II clinical trial of a combination of osteocalcin promoter-driven herpes simplex virus thymidine kinase (Ad-OC-TK) gene therapy and valacyclovir (VAL) were investigated for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: The QOL of six patients was prospectively assessed after gene therapy on days 0, 14, and 28. A modified questionnaire was created based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire's prostate cancer-specific module (EORTC QLQ-PR25). Results: The scores of all items significantly improved along with the total score. Further, bodily pain was significantly reduced on day 28. Moreover, the rate of change in the serum prostate-specific antigen levels from day 0 to day 28 was significantly correlated with the rate of change in bodily pain. Conclusion: In this clinical trial, Ad-OC-TK plus VAL treatment significantly improved the short-term QOL and bodily pain of patients with localized recurrence or bone metastases of HRPC.

KW - Adenovirus vector

KW - Clinical trial

KW - Gene therapy

KW - Hormone refractory prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=67650070011&partnerID=8YFLogxK

M3 - 記事

C2 - 19443362

AN - SCOPUS:67650070011

SN - 0250-7005

VL - 29

SP - 1533

EP - 1537

JO - Anticancer Research

JF - Anticancer Research

IS - 5

ER -

A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this